Clinical Scorecard: Incretin Trials Often Exceed Muscle-Loss Benchmarks

At a Glance

Key Highlights

• Muscle-related losses exceeded benchmarks in about two-thirds of incretin interventions.
• Semaglutide and tirzepatide showed larger reductions in body weight and muscle-related measures.
• Half of lifestyle interventions also exceeded muscle-loss benchmarks despite smaller weight reductions.
• No trials assessed objective physical function outcomes.
• Common benchmarks for muscle loss are heuristic and not clinically validated.

Guideline-Based Recommendations

Diagnosis

• Assess body composition using bioelectrical impedance analysis, dual-energy x-ray absorptiometry, or imaging techniques.

Management

• Consider pairing pharmacologic treatment with resistance exercise and adequate protein intake.

Monitoring & Follow-up

• Monitor changes in muscle-related indices and body composition during treatment.

Risks

• Potential for significant muscle loss exceeding heuristic benchmarks during weight loss interventions.

Patient & Prescribing Data

Adults with obesity, primarily younger and middle-aged individuals.

Higher-efficacy therapies are associated with greater absolute losses of fat and muscle-related tissue.

Clinical Best Practices

• Standardize body composition outcome measures in clinical trials.
• Incorporate objective measures of physical performance in future studies.
• Ensure representation of older and high-risk populations in obesity treatment trials.

References

• Annals of Internal Medicine